Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI camera could catch melanoma before It's too late

NCT ID NCT06221397

Diagnosis Sponsor: AI Labs Group S.L Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether an artificial intelligence (AI) system can help detect melanoma, a dangerous form of skin cancer. Researchers took photos of suspicious skin spots from 105 adults using a smartphone camera and let the AI analyze them. They compared the AI's results to diagnoses from skin doctors and lab tests. The goal was to see if the AI could match or improve upon expert judgment, without changing the care patients received.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based Computer-Aided Diagnosis (CAD) software
What this could lead to
If successful, this AI tool could help doctors spot skin cancer earlier and more accurately, potentially saving lives through faster treatment.
What could go wrong
This was a small, completed observational study with 105 participants. The AI's performance may not hold up in larger, more diverse populations or real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

105 people

The number who actually took part.

Started

Sep 2020

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with skin lesions with suspected malignancy seen at the Dermatology Department of the Hospital Universitario Cruces and Hospital Universitario Basurto.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with skin lesions with suspected malignancy * Age over 18 years old * Patients who consent to participate in the study by signing the Informed Consent form Exclusion Criteria: * Patients under 18 years of age

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cutaneous melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous melanoma disease melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma Melanoma (skin)

Contacts and locations

Locations

  • University Hospital of Cruces

    Barakaldo, Biscay, 48903, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.